Skip to main content
Veterinary Medicines

DUOMYXIN, 3 400 IU/ml / 10 000 IU/ml, Eye drops, powder and solvent for solution for dogs and cats

Authorised
  • NEOMYCIN SULFATE
  • POLYMYXIN B SULFATE

Product identification

Medicine name:
DUOMYXIN, 3 400 IU/ml / 10 000 IU/ml, Eye drops, powder and solvent for solution for dogs and cats
DUOMYXIN 3400 IU/ml / 10000 IU/ml silmätipat, jauhe ja liuotin liuosta varten
Active substance:
  • NEOMYCIN SULFATE
  • POLYMYXIN B SULFATE
Target species:
  • Cat
  • Dog
Route of administration:
  • Ocular use

Product details

Active substance and strength:
  • NEOMYCIN SULFATE
    17000.00
    international unit(s)
    /
    1.00
    Vial
  • POLYMYXIN B SULFATE
    50000.00
    international unit(s)
    /
    1.00
    Vial
Pharmaceutical form:
  • Eye drops, powder for solution
Withdrawal period by route of administration:
  • Ocular use
    • Cat
    • Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QS01AA30
Authorisation status:
  • Valid
Authorised in:
  • Finland
Package description:
  • Box of 1 vial of lyophilisate, 1 bottle of 5 ml solvent and 1 dropper

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • Domes Pharma
Marketing authorisation date:
Manufacturing sites for batch release:
  • Tubilux Pharma S.p.A.
Responsible authority:
  • Finnish Medicines Agency
Authorisation number:
  • 40405
Date of authorisation status change:
Reference member state:
  • Netherlands
Procedure number:
  • NL/V/0381/001
Concerned member states:
  • Austria
  • Belgium
  • Denmark
  • Finland
  • Germany
  • Greece
  • Ireland
  • Italy
  • Luxembourg
  • Norway
  • Poland
  • Portugal
  • Romania
  • Spain
  • Sweden

Documents

Summary of Product Characteristics

English (PDF)
Published on: 6/02/2024
Download

Package Leaflet and Labelling

English (PDF)
Published on: 6/02/2024
Download

Final PuAR Duomyxin NL.V.0381.001.DC v.23102023.pdf

English (PDF)
Published on: 6/02/2024
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."